newsfilter
← Latest News
GlobeNewswire·

KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference

Data highlight key pharmacokinetic properties of serdexmethylphenidate that are instrumental to its consistent and smooth release of d-MPH CELEBRATION, Fla., Jan. 11, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical